Literature DB >> 10995517

The need to lower systolic blood pressure.

S Shrivastava1, M S Kochar.   

Abstract

Systolic hypertension is the most common form of hypertension, especially in individuals aged 60 years or older. Systolic hypertension is a reflection of decreasing compliance of large arteries and is a strong independent risk factor for all cardiovascular diseases. Despite proven benefits of therapy for systolic hypertension, only 25% of patients with this condition are adequately treated to attain target blood pressures. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of high blood pressure (JNC VI) recommends the use of diuretics and long-acting dihydropyridine calcium channel blockers as first-line therapy for isolated systolic hypertension. Therapy is also guided by comorbid conditions where certain drugs may have additional benefits. The goal of therapy should be a graded reduction in blood pressure to less than 140/90 mm Hg with lower blood pressure targets in patients with coexistent diabetes or renal failure.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10995517     DOI: 10.1007/s11906-000-0024-0

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  36 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators.

Authors:  J A Staessen; L Thijs; R Fagard; E T O'Brien; D Clement; P W de Leeuw; G Mancia; C Nachev; P Palatini; G Parati; J Tuomilehto; J Webster
Journal:  JAMA       Date:  1999-08-11       Impact factor: 56.272

Review 3.  Effects of the endothelium on growth responses in arteries.

Authors:  J G De Mey; P M Schiffers
Journal:  J Cardiovasc Pharmacol       Date:  1993       Impact factor: 3.105

4.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

5.  Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study.

Authors:  S S Franklin; S A Khan; N D Wong; M G Larson; D Levy
Journal:  Circulation       Date:  1999-07-27       Impact factor: 29.690

6.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

7.  Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study.

Authors:  M Ravid; R Lang; R Rachmani; M Lishner
Journal:  Arch Intern Med       Date:  1996-02-12

8.  Early predictors of 15-year end-stage renal disease in hypertensive patients.

Authors:  H M Perry; J P Miller; J R Fornoff; J D Baty; M P Sambhi; G Rutan; D W Moskowitz; S E Carmody
Journal:  Hypertension       Date:  1995-04       Impact factor: 10.190

9.  The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group.

Authors:  S Klahr; A S Levey; G J Beck; A W Caggiula; L Hunsicker; J W Kusek; G Striker
Journal:  N Engl J Med       Date:  1994-03-31       Impact factor: 91.245

Review 10.  Blood pressure lowering for the secondary prevention of stroke: rationale and design for PROGRESS.

Authors: 
Journal:  J Hypertens Suppl       Date:  1996-09
View more
  3 in total

Review 1.  Trials in isolated systolic hypertension: an update.

Authors:  Bernard Waeber
Journal:  Curr Hypertens Rep       Date:  2003-08       Impact factor: 5.369

Review 2.  Trials in isolated systolic hypertension: an update.

Authors:  Bernard Waeber
Journal:  Curr Cardiol Rep       Date:  2003-11       Impact factor: 2.931

Review 3.  Fixed low-dose combination therapy for hypertension.

Authors:  Bernard Waeber
Journal:  Curr Hypertens Rep       Date:  2002-08       Impact factor: 5.369

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.